What to know first
Answer-first notes for searchers, readers, and clinician conversations.
How to read this watchlist
This page is a source-backed editorial watchlist, not a treatment ranking. Status labels use four plain categories: approved for a specific label, investigational in human trials, research-only or mechanism-heavy, and source-limited when the public evidence trail is too thin for confident consumer interpretation.
Retatrutide
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. The published phase 2 obesity trial and ClinicalTrials.gov records make it a high-interest pipeline therapy, but it is not an approved consumer treatment and this page does not provide access, dosing, or sourcing guidance.
CagriSema, amycretin, and amylin combinations
CagriSema combines GLP-1 and amylin-pathway activity. Amycretin and other amylin-plus-incretin approaches are adjacent because they signal a move toward multi-pathway satiety medicines. Public data makes the category important to watch, but approval status, label language, real-world tolerability, and access remain key unknowns until regulatory review and broader use.
Oral and next-generation formats
Orforglipron, higher-dose oral semaglutide programs, and other oral incretins may compete on convenience, manufacturing scale, adherence, access, metabolic outcomes, cardiovascular data, and durability. Oral semaglutide has approved diabetes uses; orforglipron and many higher-dose obesity programs still need product-specific regulatory review before readers should treat them as care options.
How to read this watchlist
This page is a source-backed editorial watchlist, not a treatment ranking. Status labels use four plain categories: approved for a specific label, investigational in human trials, research-only or mechanism-heavy, and source-limited when the public evidence trail is too thin for confident consumer interpretation.
Snapshot reviewed June 22, 2026. Trial registries, PubMed abstracts, FDA labels, and regulator pages can change, so each claim below is framed as a review point rather than evergreen medical advice.
- Approved does not mean right for every person.
- Investigational does not mean available care or a product to seek out.
- Research-only and source-limited topics should not be turned into self-experimentation protocols.
Retatrutide
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. The published phase 2 obesity trial and ClinicalTrials.gov records make it a high-interest pipeline therapy, but it is not an approved consumer treatment and this page does not provide access, dosing, or sourcing guidance.
CagriSema, amycretin, and amylin combinations
CagriSema combines GLP-1 and amylin-pathway activity. Amycretin and other amylin-plus-incretin approaches are adjacent because they signal a move toward multi-pathway satiety medicines. Public data makes the category important to watch, but approval status, label language, real-world tolerability, and access remain key unknowns until regulatory review and broader use.
Oral and next-generation formats
Orforglipron, higher-dose oral semaglutide programs, and other oral incretins may compete on convenience, manufacturing scale, adherence, access, metabolic outcomes, cardiovascular data, and durability. Oral semaglutide has approved diabetes uses; orforglipron and many higher-dose obesity programs still need product-specific regulatory review before readers should treat them as care options.
MASH and metabolic-liver crossover
Mazdutide, pemvidutide, survodutide, and other glucagon or incretin-adjacent programs also matter because metabolic therapy is expanding beyond weight-only headlines into liver fat, cardiometabolic risk, and obesity complications. These topics need careful claim separation: a MASH or liver-fat endpoint is not the same as an obesity approval, and vice versa.
Status-labeled pipeline watchlist
Reviewed June 22, 2026 · labels can change
| Therapy/topic | Status label | Source trail | Editorial boundary |
|---|---|---|---|
| Oral semaglutide | Approved for specific diabetes-product labels; higher-dose obesity programs need product-specific review | FDA labels / NIDDK | Do not generalize one oral product or dose to every GLP-1 pill conversation. |
| Orforglipron | Investigational oral small-molecule GLP-1 receptor agonist | ClinicalTrials.gov search retrieved June 22, 2026; PubMed literature trail | No access, dosing, or pharmacy guidance until a regulator approves a product and indication. |
| Retatrutide | Investigational triple GLP-1/GIP/glucagon agonist | NEJM/PubMed phase 2 trial plus ClinicalTrials.gov records | Strong trial interest is not the same as approved care or personal-fit evidence. |
| CagriSema / cagrilintide + semaglutide | Investigational amylin-plus-GLP-1 combination strategy | ClinicalTrials.gov CagriSema records retrieved June 22, 2026; PubMed cagrilintide search | Keep the fixed-combination product, component mechanisms, and comparator claims separate. |
| Amycretin | Investigational amylin-plus-GLP-1 concept | ClinicalTrials.gov amycretin record retrieved June 22, 2026; PubMed search | Treat as pipeline research; avoid social-media claims that imply availability or superiority. |
| Mazdutide | Investigational dual GLP-1/glucagon metabolic therapy | ClinicalTrials.gov IBI362/mazdutide records and PubMed search | Source-limited for US readers; avoid importing claims across countries, endpoints, or regulatory paths. |
| Pemvidutide | Investigational GLP-1/glucagon metabolic-liver crossover therapy | ClinicalTrials.gov pemvidutide records and PubMed MASH/obesity search | Liver-fat or MASH endpoints should not be rewritten as a general weight-loss approval. |
| Survodutide | Investigational GLP-1/glucagon receptor dual agonist | ClinicalTrials.gov survodutide records and PubMed obesity/MASH search | Track obesity and MASH programs separately; do not rank it against approved GLP-1s. |
| Wellness-market research peptides | Research-only or source-limited unless a specific product and indication are approved | PubMed / ClinicalTrials.gov / FDA labels | Do not turn research-use listings, animal studies, or clinic charts into human protocols. |
GLP-1 guide
Use the basics page for approved-medicine context before comparing pipeline mechanisms.
Doctor questions
Turn watchlist curiosity into clinician questions, not purchase or dosing decisions.
Evidence + standards
Review how The Glow Diary separates labels, trials, mechanisms, and unsupported claims.
Sources and further reading
These links are included to make the evidence trail visible. They are not sponsor links and do not replace product-specific medical advice.